Sees FY24 revenue $836M-$838M, consensus $840.16M
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics, MD Anderson forms 5-year strategic alliance
- Myriad Genetics price target lowered to $13 from $15 at BofA
- Myriad Genetics provides an update on engagement with UnitedHealthcare
- Myriad Genetics’ portfolio elevated by updated NCCN prostate cancer guidelines
- Myriad Genetics initiated with a Neutral at UBS